Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice

Diabetes

Volumn 57, Issue 5, 2008, Pages 1331-1339

  Kim, Su Jin ^a   Nian, Cuilan ^a   Doudet, Doris J ^a   Mcintosh, Christopher H S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL PROTECTION; CONTROLLED STUDY; DIET; DRUG EFFECT; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEEDING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRAFT REJECTION; GRAFT SURVIVAL; HEPATOCYTE TRANSPLANTATION; HORMONE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STREPTOZOCIN DIABETES; ANIMAL; BLOOD; C57BL MOUSE; CULTURE TECHNIQUE; CYTOLOGY; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; METABOLISM; PANCREAS ISLET;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; CELL CULTURE TECHNIQUES; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GRAFT SURVIVAL; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; PYRAZINES; TRIAZOLES;

EID: 48449086945     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1639     Document Type: Article

References (40)

1. Shapiro AMJ, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238, 2000
2. Collaborative Islet Transplant Registry Annual Reports [article online]. Available from https://web.emmes.com/study/isl/reports/reports.htm. Accessed 20 December 2007
3. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AMJ: Five-year follow-up after clinical islet transplantation. Diabetes 54:2060-2069, 2005
4. Boker A, Rothenberg L, Hernandez C, Kenyon NS, Ricordi C, Alejandro R: Human islet transplantation: update. World J Surg 25:481-486, 2001
5. Robertson RP: Intrahepatically transplanted islets-strangers in a strange land [Editorial]. Endocrinology 8:5416-5417, 2002
6. Davalli AM, Scaglia L, Zangen DH, Hollister J, Bonner-Weir S, Weir GC: Vulnerability of islets in the immediate posttrransplantation period: dynamic changes in structure and function. Diabetes 45:1161-1167, 1996
7. Narang AS, Mahato RI: Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 58:194-243, 2006
8. Brubaker PL, Drucker DJ: Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145:2653-2659, 2004
9. Drucker DJ: The biology of incretin hormones. Cell Metab 3:153-165, 2006
10. Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, Pederson RA, McIntosh CHS: Glucose-dependent insulinotropic polypep-tide promotes beta-(INS-1) cell survival via cyclic adenosine monophos-phate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144:4433-4445, 2003
11. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, McIntosh CHS: Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 280:22297-22307, 2005
12. Kim SJ, Nian C, Widenmaier S, McIntosh CHS: Glucose-dependent insuli-notropic polypeptide (GIP) mediated up-regulation of β-cell antiapoptotic Bcl-2 gene expression is coordinated by cAMP-response element binding protein (CREB) and cAMP-responsive CREB coactivator 2 (TORC2). Mol Cell Biol 28:1644-1656, 2008
13. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, pep-tide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
14. Kieffer TJ, McIntosh CHS, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
15. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
16. Lambeir AM, Durinx C, Scharpe S, De Meester I: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sc 40:209-294, 2003
17. McIntosh CHS, Demuth H-U, Kim SJ, Pospisilik JA, Pederson RA: Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus Int J Biochem Cell Biol 38:860-872, 2006
18. Ahrén B: Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 30:1344-1350, 2007
19. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705, 2006
20. Creutzfeldt WO, Kleine N, Willms B, 0rskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586, 1996
21. Dupre J: Glycaemic effects of incretins in type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept 128:149-157, 2005
22. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA: Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozo-tocin-induced diabetic rats. Diabetes 52:741-750, 2003
23. Pospisilik JA, Ehses JA, Doty T, McIntosh CH, Demuth HU, Pederson RA: Dipeptidyl peptidase IV inhibition in animal models of diabetes. Adv Exp Med Biol 524:281-291, 2003
24. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE: (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151, 2005
25. Salvalaggio PR, Deng S, Ariyan CE, Millet I, Zawalich WS, Basadonna GP, Rothstein DM: Islet filtration: a simple and rapid new purification. Transplantation 74:877-879, 2002
26. Becker TC, Noel RJ, Coats WS, Gómez-Foix AM, Alam T, Gerard RD, Newgard CB: Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 43:161-189, 1994
27. Kim SJ, Doudet DJ, Studenov AR, Ruth TJ, Gambhir SS, McIntosh CHS: Seeing is believing-in vivo functional real-time imaging of transplanted islets using positron emission tomography (PET). DOI: 10.1038/ nprot.2006.491 [article online]. Nature Protocols Network. Available from: http://www.natureprotocols. com/2006/12/21/seeing-is-believing-in-vivo-fu.php
28. Kim SJ, Doudet DJ, Studenov AR, Ruth TJ, Gambhir SS, McIntosh CHS: Quantitative in vivo imaging of transplanted islets using microPET (positron emission tomography) scanning. Nat Med 12:1423-1428, 2006
29. Kim JS, Lee JS, Im KC, Kim SJ, Kim SY, Lee DS, Moon DH: Performance measurement of the microPET Focus 120 Scanner. J Nuc Med 48:1527-1535, 2007
30. +. IEEE Trans Nucl Sci 45:1096-1103, 1998
31. Chatziioannou A, Qi J, Moore A, Annala A, Nguyen K, Leahy R, Cherry SR: Comparison of 3-D maximum a posteriori and filtered back projection algorithms for high-resolution animal imaging with microPET. IEEE Trans Med Imag 19:507-512, 2000
32. Richards SK, Parton LE, Leclerc I, Rutter GA, Smith RM: Over-expression of AMP-activated protein kinase impairs pancreatic β-cell function in vivo. J Endocrinol 187:225-235, 2005
33. Mu J, Woods J, Zhou Y-P, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang B: Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704, 2006
34. Demuth H-U, McIntosh CHS, Pederson RA: Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751:33-44, 2005
35. Dufrane D, van Steenberghe M, Guiot Y, Goebbels R-M, Sakiez A, Gianello P: Streptozotocin-induced diabetes in large animals (pigs/primates): role of GLUT2 transporter and β-cell plasticity. Transplantation 81:36-45, 2006
36. Robertson RP: Estimation of β-cell mass by metabolic tests: necessary, but how sufficient? Diabetes 56:2420-2424, 2007
37. Yu Y, Annala AJ, Barrio JR, Toyokuni T, Satyamurthy N, Namavari M, Cherry SR, Phelps ME, Herschman HR, Gambhir SS: Quantification of target gene expression by imaging reporter gene expression in living animals. Nat Med 6:933-937, 2000
38. Gambhir SS, Bauer E, Black ME, Liang Q, Kokoris MS, Barrio JR, Iyer M, Namavari M, Phelps ME, Herschman HR: A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad SciUSA97:2785-2790, 2000
39. Lu Y, Dang H, Middleton B, Zhang Z, Washburn L, Stout DB, Campbell-Thompson M, Atkinson MA, Phelps M, Gambhir SS, Tian J, Kaufman DL: Noninvasive imaging of islet grafts using positron-emission tomography. Proc Natl Acad Sci USA 103:11294-11299, 2006
40. Lu Y, Dang H, Middleton B, Campbell-Thompson M, Atkinson MA, Gambhir SS, Tian J, Kaufman DL: Long-term monitoring of transplanted islets using positron emission tomography. Mol Ther 14:851-856, 2006